Quest Diagnostics launches HCV obstetrics panel

2020 04 02 20 02 8495 Quest Diagnostics 400

Quest Diagnostics on Wednesday announced the launch of an obstetrics laboratory test panel to enable physicians to screen eligible pregnant people for hepatitis C (HCV) with other laboratory tests typically ordered during early pregnancy.

The company developed the new test panel to include HCV antibody testing with a reflex to quantitative real-time PCR testing, in response to findings from a health trends study published in Obstetrics & Gynecology.

The peer-reviewed study, published by Quest investigators in June, found that less than 41% of pregnant people were screened for HCV in 2021, and individuals with Medicaid health insurance were screened at rates 25% to 35% lower than those with commercial insurance.

Obstetric panels are typically performed early in pregnancy and include guideline-recommended tests, such as complete blood count (CBC), blood typing, hepatitis B, syphilis, and rubella, to help guide clinical decisions affecting the pregnancy and mother's health.

Page 1 of 23
Next Page